These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 32617667)

  • 21. Survival results of a randomised two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of S-1 plus cisplatin (SC) and paclitaxel plus cisplatin (PC) followed by D2 gastrectomy for resectable advanced gastric cancer.
    Yoshikawa T; Morita S; Tanabe K; Nishikawa K; Ito Y; Matsui T; Fujitani K; Kimura Y; Fujita J; Aoyama T; Hayashi T; Cho H; Tsuburaya A; Miyashita Y; Sakamoto J
    Eur J Cancer; 2016 Jul; 62():103-11. PubMed ID: 27244537
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Downstaging of lymph node metastasis after neoadjuvant intraperitoneal and systemic chemotherapy in gastric carcinoma with peritoneal metastasis.
    Hao Y; Liu Y; Ishibashi H; Wakama S; Nishino E; Yonemura Y
    Eur J Surg Oncol; 2019 Aug; 45(8):1493-1497. PubMed ID: 30948161
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment using oxaliplatin and S-1 adjuvant chemotherapy for pathological stage III gastric cancer: a multicenter phase II study (TOSA trial) protocol.
    Namikawa T; Maeda H; Kitagawa H; Oba K; Tsuji A; Yoshikawa T; Kobayashi M; Hanazaki K
    BMC Cancer; 2018 Feb; 18(1):186. PubMed ID: 29439671
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preoperative versus postoperative docetaxel-cisplatin-fluorouracil (TCF) chemotherapy in locally advanced resectable gastric carcinoma: 10-year follow-up of the SAKK 43/99 phase III trial.
    Fazio N; Biffi R; Maibach R; Hayoz S; Thierstein S; Brauchli P; Bernhard J; Stupp R; Andreoni B; Renne G; Crosta C; Morant R; Chiappa A; Luca F; Zampino MG; Huber O; Goldhirsch A; de Braud F; Roth AD; ;
    Ann Oncol; 2016 Apr; 27(4):668-73. PubMed ID: 26712905
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinical features and prognosis analysis of 21 gastric cancer patients with pathological complete response after neoadjuvant chemotherapy].
    Peng L; Yang W; Zhang Z; Liu H; Hua Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Oct; 20(10):1168-1173. PubMed ID: 29130233
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of D2 gastrectomy in gastric cancer with clinical para-aortic lymph node metastasis.
    Zheng XH; Zhang W; Yang L; Du CX; Li N; Xing GS; Tian YT; Xie YB
    World J Gastroenterol; 2019 May; 25(19):2338-2353. PubMed ID: 31148905
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer.
    Yoshikawa T; Sasako M; Yamamoto S; Sano T; Imamura H; Fujitani K; Oshita H; Ito S; Kawashima Y; Fukushima N
    Br J Surg; 2009 Sep; 96(9):1015-22. PubMed ID: 19644974
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II trial of preoperative S-1 plus cisplatin followed by surgery for initially unresectable locally advanced gastric cancer.
    Inoue K; Nakane Y; Kogire M; Fujitani K; Kimura Y; Imamura H; Tamura S; Okano S; Kwon AH; Kurokawa Y; Shimokawa T; Takiuchi H; Tsujinaka T; Furukawa H
    Eur J Surg Oncol; 2012 Feb; 38(2):143-9. PubMed ID: 22154885
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II Study of Induction Chemotherapy with Docetaxel, Capecitabine, and Cisplatin Plus Bevacizumab for Initially Unresectable Gastric Cancer with Invasion of Adjacent Organs or Paraaortic Lymph Node Metastasis.
    Kim JH; Park SR; Ryu MH; Ryoo BY; Kim KP; Kim BS; Yoo MW; Yook JH; Kim BS; Kim J; Byeon SJ; Kang YK
    Cancer Res Treat; 2018 Apr; 50(2):518-529. PubMed ID: 28546521
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adjuvant chemotherapy for gastric cancer: a randomised phase 3 trial of mitomycin-C plus either short-term doxifluridine or long-term doxifluridine plus cisplatin after curative D2 gastrectomy (AMC0201).
    Kang YK; Chang HM; Yook JH; Ryu MH; Park I; Min YJ; Zang DY; Kim GY; Yang DH; Jang SJ; Park YS; Lee JL; Kim TW; Oh ST; Park BK; Jung HY; Kim BS
    Br J Cancer; 2013 Apr; 108(6):1245-51. PubMed ID: 23449357
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [A case of advanced gastric cancer exhibiting pathological complete response after neoadjuvant chemotherapy].
    Taniguchi M; Watanabe Y; Shirakawa M; Nakano H; Endo W; Hamano R; Tsujie M; Yano H
    Gan To Kagaku Ryoho; 2013 Nov; 40(12):2298-300. PubMed ID: 24394091
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neoadjuvant chemotherapy for gastric cancer. Is it a must or a fake?
    Reddavid R; Sofia S; Chiaro P; Colli F; Trapani R; Esposito L; Solej M; Degiuli M
    World J Gastroenterol; 2018 Jan; 24(2):274-289. PubMed ID: 29375213
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [A case of advanced gastric cancer responding to combined systemic and intraperitoneal chemotherapy with docetaxel, cisplatin, and S-1].
    Yasui T; Mukubo H; Sato N; Kita I; Fushida S
    Gan To Kagaku Ryoho; 2013 Nov; 40(12):2229-31. PubMed ID: 24394068
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neoadjuvant chemoradiotherapy followed by D2 gastrectomy in locally advanced gastric cancer.
    Kim MS; Lim JS; Hyung WJ; Lee YC; Rha SY; Keum KC; Koom WS
    World J Gastroenterol; 2015 Mar; 21(9):2711-8. PubMed ID: 25759540
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Survival Benefit of Neoadjuvant Chemotherapy with S-1 Plus Docetaxel for Locally Advanced Gastric Cancer: A Propensity Score-Matched Analysis.
    Kano M; Hayano K; Hayashi H; Hanari N; Gunji H; Toyozumi T; Murakami K; Uesato M; Ota S; Matsubara H
    Ann Surg Oncol; 2019 Jun; 26(6):1805-1813. PubMed ID: 30977014
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Five-year outcomes of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for stage III gastric cancer after curative D2 gastrectomy (OGSG1002).
    Fujitani K; Tamura S; Kimura Y; Matsuyama J; Imamura H; Yamamoto K; Fujita J; Iijima S; Ueda S; Kurokawa Y; Shimokawa T; Satoh T;
    Gastric Cancer; 2020 May; 23(3):520-530. PubMed ID: 31667688
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [A Case of Gastric Cancer Responding to Neoadjuvant Chemotherapy Leading to Histological Change to Grade 3].
    Osakabe H; Katayanagi S; Makuuchi Y; Shigoka M; Sumi T; Tsuchida A; Kawachi S
    Gan To Kagaku Ryoho; 2016 Nov; 43(12):2228-2230. PubMed ID: 28133278
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neoadjuvant chemotherapy with S-1 and CDDP in advanced gastric cancer.
    Kochi M; Fujii M; Kanamori N; Kaiga T; Takahashi T; Kobayashi M; Takayama T
    J Cancer Res Clin Oncol; 2006 Dec; 132(12):781-5. PubMed ID: 16804723
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neoadjuvant intraperitoneal and systemic chemotherapy for gastric cancer patients with peritoneal dissemination.
    Fujiwara Y; Takiguchi S; Nakajima K; Miyata H; Yamasaki M; Kurokawa Y; Okada K; Mori M; Doki Y
    Ann Surg Oncol; 2011 Dec; 18(13):3726-31. PubMed ID: 21584835
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term follow-up of a pilot phase II study with neoadjuvant epidoxorubicin, etoposide and cisplatin in gastric cancer.
    Barone C; Cassano A; Pozzo C; D'Ugo D; Schinzari G; Persiani R; Basso M; Brunetti IM; Longo R; Picciocchi A
    Oncology; 2004; 67(1):48-53. PubMed ID: 15459495
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.